BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ERX1000 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ERX1000\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07570758-275@assetmemo.bio
DTSTAMP:20261121T005858Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:ERX1000: Phase 2 readout est. (NCT07570758)
DESCRIPTION:ERX1000\, phase 2\, Obesity.\nStudy: A Phase 2A Clinical Trial 
 to Assess the Safety and Tolerability of ERX1000 in Men and Women for the 
 Treatment of Obesity.\nEstimated primary completion: May 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/erx1000#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07570758
URL:https://assetmemo.bio/drug/erx1000#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
